Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937462 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL18600520 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL16585556 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4EALOX15MEN1 | |
| SCHEMBL28235242 | 0.82 | MGLL (0.46) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL27926749 | 0.82 | MGLL (0.46) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL28311119 | 0.81 | ALOX15 (0.58) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL19284723 | 0.80 | HTR6 (0.65) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL18600532 | 0.80 | CYP1A2 (0.50) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL11087705 | 0.80 | KDM4E (0.49) | ALDH1A1LMNAKDM4EALOX15CYP1A2 | |
| SCHEMBL1491206 | 0.80 | KMT2A (0.64) | ALDH1A1LMNAALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3495347-A1 | NEW PROCESS FOR THE SYNTHESIS OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE | LEK Pharmaceuticals d.d. (SI) | 2019-06-12 | — | — | EP | disclosed |
| US-20180072690-A1 | Methods for Making Serotonin Reuptake Inhibitors | CIPLA LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| EP-3274330-A1 | METHOD FOR MAKING SEROTONIN REUPTAKE INHIBITORS | Cipla Limited (IN) | 2018-01-31 | — | — | EP | disclosed |
| US-9493409-B2 | Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine | LEK PHARMACEUTICALS D.D. (SI) | 2016-11-15 | — | — | US | disclosed |
| WO-2016151328-A1 | METHOD FOR MAKING SEROTONIN REUPTAKE INHIBITORS | CIPLA LIMITED (IN) | 2016-09-29 | — | — | WO | disclosed |
| US-20160060215-A1 | New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)Piperazine | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-03 | — | — | US | disclosed |
| EP-2981520-A1 | NEW PROCESS FOR THE SYNTHESIS OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE | LEK Pharmaceuticals d.d. (SI) | 2016-02-10 | — | — | EP | disclosed |
| WO-2015155153-A1 | SYNTHESIS OF VORTIOXETINE VIA (2,4-DIMETHYLPHENYL)(2-IODOPHENYL)SULFANE INTERMEDIATE | LEK PHARMACEUTICALS D.D. (SI) | 2015-10-15 | — | — | WO | disclosed |
| EP-2930171-A1 | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate | LEK Pharmaceuticals d.d. (SI) | 2015-10-14 | — | — | EP | disclosed |
| EP-2894154-A1 | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates | LEK Pharmaceuticals d.d. (SI) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015079018-A1 | SYNTHESIS OF VORTIOXETINE VIA (2-(PIPERAZINE-1 -YL)PHENVL)LITHIUM INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2015-06-04 | — | — | WO | disclosed |
| EP-2878596-A1 | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates | LEK Pharmaceuticals d.d. (SI) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014191548-A1 | NEW PROCESS FOR THE SYNTHESIS OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014161976-A1 | NEW PROCESS FOR THE SYNTHESIS OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE | LEK PHARMACEUTICALS D.D. (SI) | 2014-10-09 | — | — | WO | disclosed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885LMNA 715/4885KDM4E 3899/4885 |
| US-20180072690-A1 | Methods for Making Serotonin Reuptake Inhibitors | SLC6A4, SLC6A2, SLC6A3 | ALDH1A1 537/4885LMNA 777/4885KDM4E 1633/4885 |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | ALDH1A1 1298/4885LMNA 4200/4885KDM4E 3994/4885 |
| US-20160060215-A1 | New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)Piperazine | HTR5A, HTR2A, HTR2C | ALDH1A1 300/4885LMNA 4483/4885KDM4E 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.